Cambridge Healthtech Institute’s Inaugural

Targeting Fibrosis

Developing Medical Therapies for Fibrotic Diseases

September 18-19, 2019


The incidence of fibrosis, a normal part of wound healing, but also, under persistent inflammation or injury, a disease process that contributes to organ damage, has been steadily increasing over the past decade. This could be partly due to the percentage of elderly and thus chronic disease and inflammation rising in the population. Activity in the drug development arena for fibrosis has also grown. Much of the progress has been spurred by the fields of autoimmunity and inflammation which are revealing common mechanisms for fibrosis across the organs where fibrosis is most frequently observed: lung, liver, heart, kidney and skin. The approval of two drugs for a form of lung fibrosis, idiopathic fibrosis (IPF), has also accelerated progress in the field. However it is likely that multiple therapeutic approaches for treating fibrosis will be necessary because of the many contributors to the condition. For this reason, CHI’s Inaugural Targeting Fibrosis conference aims to convene the leading fibrosis researchers from academics and industry working across organ types, as well as immunology and inflammation investigators to share progress and shape future directions in this burgeoning field of new drug discovery.


This Fibrosis conference is preceded by a 1.5 day conference on the related field of NASH at the same Discovery on Target event.


Who should attend: Discovery Biologists, Discovery Chemists, Medicinal Chemists, Pharmacologists, Immunologists, Directors of Fibrosis, Researchers, Principal Scientists, Post-doctoral Fellows, Professors, Assistant Professors, Scientists, Graduate Students, Autoimmunity Researchers, Kidney Disease Researchers, Metabolic Disease Researchers.


Coverage will include, but is not limited to:                                        

  • Promising fibrosis targets: integrins, TGFb, components of the extracellular matrix
  • Emerging targets: GPCRs, growth factors, PD1, STAT3, IL17A
  • Autoimmune and inflammation connections
  • Common mechanisms or targets across fibrosis-prone organs: lung, liver, heart, kidney, skin
  • Organ specific fibrosis drug candidates and potential for cross-over fibrotic targets


If you would like to submit a proposal to give a presentation at this meeting, please click here.


The deadline for priority consideration is February 27, 2019.


All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


For more details on the conference, please contact:
Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252


For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286

Premier Sponsors

Ablexis Alivamab_stacked



OmniAb Ligand_Pharmaceuticals